Back to Search Start Over

CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Authors :
Pavelko KD
Hansen MJ
Pease LR
Source :
Cancer research [Cancer Res] 2009 Apr 01; Vol. 69 (7), pp. 3114-20. Date of Electronic Publication: 2009 Mar 10.
Publication Year :
2009

Abstract

Vaccine strategies for cancer immunotherapy have focused on peptide ligands with high affinity for MHC class I. Largely, these vaccines have not been therapeutic. We have examined the peptide specificity of a strongly protective T-cell response that eradicates established B16 melanoma and find that the recognized epitope is generated by a low-affinity MHC class I ligand from tyrosinase-related protein 1 (TRP1). Cytotoxic T-cell responses are induced against TRP1(222-229) by several vaccination schemes using a Toll-like receptor agonist, T regulatory cell depletion, or the immune modulator B7-DCXAb to drive immunity. TRP1(222) CTL are generated from multiple antigen sources, including antigens expressed by tumors growing in situ, tumor cell lysates, and peptide vaccines. The key finding in this study is that protection from freshly implanted or established B16 tumors is primarily mediated by TRP1(222)-specific CTL and not by CTL specific for more traditional melanoma antigens such as TRP2 or gp100. This finding challenges the assumption that the optimal peptide antigens for cancer vaccines are high-affinity MHC ligands. We propose that when administered appropriately, native low-affinity MHC ligands are optimal inducers of immunotherapeutic CTL.

Details

Language :
English
ISSN :
1538-7445
Volume :
69
Issue :
7
Database :
MEDLINE
Journal :
Cancer research
Publication Type :
Academic Journal
Accession number :
19276379
Full Text :
https://doi.org/10.1158/0008-5472.CAN-08-2448